Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zdravka Medarova
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Transcode Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Medarova is a co-founder of and owns equity in Transcode Therapeutics, a preclinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of microRNA therapeutics for treating metastatic cancer. Transcode Therapeutics has an interest in licensing technology being used in this research grant. The company would therefore have an interest in the results of the research. The institution determined that Dr. Medarova’s financial interest in Transcode Therapeutics could directly and significantly affect the design, conduct, or reporting of the research.
In vivo methodology for the discovery and validation of miRNA biomarkers in cancer
In the proposed research, we will develop and test novel methodology that would allow the discovery and validation of miRNA biomarkers in cancer. The methodology will employ nanosensors capable of reporting on miRNA expression in vivo. The performance of the technology will be tested in a model of breast cancer metastasis. What is unique about the nanosensors described here is that they allow studies in vivo in an authentic anatomical and physiologic environment and thus they reflect the true dynamics of the metastatic process. �
Filed on September 14, 2018.
Tell us what you know about Zdravka Medarova's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Zdravka Medarova filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.